Slash Boxes

SoylentNews is people

posted by LaminatorX on Sunday December 14 2014, @08:19AM   Printer-friendly
from the good-drugs dept.

Andrew Pollack reports at the NYT that a federal judge has blocked an attempt by the drug company Actavis to halt sales of an older form of its Alzheimer’s disease drug Namenda in favor of a newer version with a longer patent life after New York’s attorney general filed an antitrust lawsuit accusing the drug company of forcing patients to switch to the newer version of the widely used medicine to hinder competition from generic manufacturers. “Today’s decision prevents Actavis from pursuing its scheme to block competition and maintain its high drug prices,” says Eric Schneiderman, the New York attorney general. “Our lawsuit against Actavis sends a clear message: Drug companies cannot illegally prioritize profits over patients.” The case involves a practice called product hopping where brand name manufacturers (“product hoppers”) make a slight alteration to their prescription drug (PDF) and engage in marketing efforts to shift consumers from the old version to the new to insulate the drug company from generic competition for several years. For its part Actavis argued that an injunction would be “unprecedented and extraordinary” and would cause the company “great financial harm, including unnecessary manufacturing and marketing costs.” Namenda has been a big seller. In the last fiscal year, the drug generated $1.5 billion in sales. The drug costs about $300 a month.

This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 2) by sjames on Sunday December 14 2014, @05:18PM

    by sjames (2882) on Sunday December 14 2014, @05:18PM (#125961) Journal

    Further, it's not as if another manufacturer can just start cranking out the generic the next day. They are probably already planning to start production at or near the expiration date of the patent. Moving that date up by 6 months won't move the generic availability up.

    Starting Score:    1  point
    Karma-Bonus Modifier   +1  

    Total Score:   2  
  • (Score: 2) by frojack on Sunday December 14 2014, @09:24PM

    by frojack (1554) Subscriber Badge on Sunday December 14 2014, @09:24PM (#125995) Journal

    Sure they could.
    They can get their generic approved ahead of time.
    They could have a warehouse full of the drug.

    They just can't sell one single pill until the patent expires.
    They can claim that this manufacture is for testing and in preparation for their regulatory requirements, because the US has a "research"
    safe harbor clause. []

    No, you are mistaken. I've always had this sig.
    • (Score: 2) by sjames on Monday December 15 2014, @01:37AM

      by sjames (2882) on Monday December 15 2014, @01:37AM (#126048) Journal

      Yes, and what they are doing probably is all timed out to go on sale in June, not tomorrow.

      • (Score: 2) by bob_super on Monday December 15 2014, @10:41PM

        by bob_super (1357) on Monday December 15 2014, @10:41PM (#126333)

        6 months at $1.5B/year?
        If you're the only "generic" supplier for 6 months, you could easily pocket 10-50% of that. You'll find that a lot of things can happen if the take is 75 to 375 millions...
        Heck, even the Indian Space Agency would get involved, that's one more Mars mission right there!